Ready for rescue – new nasally administered glucagon for severe hypoglycaemia available in Canada

Eli Lilly

23 January 2020 - Eli Lilly Canada introduces Baqsimi, another Canadian innovation to help manage diabetes complications.

Eli Lilly Canada is pleased to announce the approval and availability of a new rescue treatment for severe hypoglycemia, demonstrating Lilly’s commitment to simplifying diabetes management through medicines and patient solutions. The formulation was discovered in Canada and is changing the lives of people with diabetes around the world. Baqsimi (glucagon nasal powder 3 mg) was approved by Health Canada with ethical status, making it available at the pharmacy with or without a prescription. 

Baqsimi is indicated for the treatment of severe hypoglycemic reactions when impaired consciousness precludes oral carbohydrates, which may occur in the management of insulin-treated patients with diabetes mellitus, whether Type 1 or Type 2.

Read Eli Lilly press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Outcome , Medicine , Canada